Table of Contents
ISRN Endocrinology
Volume 2013, Article ID 858690, 8 pages
http://dx.doi.org/10.1155/2013/858690
Research Article

The Effect of Pioglitazone on Antioxidant Levels and Renal Histopathology in Streptozotocin-Induced Diabetic Rats

1Department of Internal Medicine, Manisa Government Hospital, 45000 Manisa, Turkey
2Division of Endocrinology, Department of Internal Medicine, Adnan Menderes University Medical Faculty, 09100 Aydin, Turkey
3Department of Medical Biochemistry, Adnan Menderes University Medical Faculty, 09100 Aydin, Turkey
4Department of Pathology, Adnan Menderes University Medical Faculty, 09100 Aydin, Turkey

Received 21 February 2013; Accepted 7 April 2013

Academic Editors: B. Larijani and V. Pezzi

Copyright © 2013 Munire Kuru Karabas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin depended diabetes mellitus,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993. View at Google Scholar
  3. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, “Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64),” Kidney International, vol. 63, no. 1, pp. 225–232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. B. A. Perkins, L. H. Ficociello, K. H. Silva, D. M. Finkelstein, J. H. Warram, and A. S. Krolewski, “Regression of microalbuminuria in type 1 diabetes,” The New England Journal of Medicine, vol. 348, no. 23, pp. 2285–2293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Giacco and M. Brownlee, “Oxidative stres and diabetic complications,” Circulation Research, vol. 107, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar
  6. N. Vasavada and R. Agarwal, “Role of oxidative stress in diabetic nephropathy,” Advances in Chronic Kidney Disease, vol. 12, no. 2, pp. 146–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. H. B. Lee, M. R. Yu, Y. Yang, Z. Ziang, and H. Ha, “Reactive oxygen species-regulated signaling pathways in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, supplement 3, pp. S241–S245, 2003. View at Publisher · View at Google Scholar
  8. D. Suzuki, T. Miyata, N. Saotome et al., “Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions,” Journal of the American Society of Nephrology, vol. 10, no. 4, pp. 822–832, 1999. View at Google Scholar · View at Scopus
  9. H. Ha and K. H. Kim, “Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C,” Diabetes Research and Clinical Practice, vol. 45, no. 2-3, pp. 147–151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ceriello, A. Morocutti, F. Mercuri et al., “Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy,” Diabetes, vol. 49, no. 12, pp. 2170–2177, 2000. View at Google Scholar · View at Scopus
  11. S. M. Son, “Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes,” Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. S65–S70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Schoonjans and J. Auwerx, “Thiazolidinediones: an update,” The Lancet, vol. 355, no. 9208, pp. 1008–1010, 2000. View at Google Scholar · View at Scopus
  13. P. A. Sarafidis, P. I. Georgianos, and A. N. Lasaridis, “PPAR-γ agonism for cardiovascular and renal protection,” Cardiovascular Therapeutics, vol. 29, no. 6, pp. 377–384, 2011. View at Publisher · View at Google Scholar
  14. M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel, “One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 1, pp. 141–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed, “Rosiglitazone monotherapy is effective in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 86, pp. 280–288, 2001. View at Google Scholar
  16. R. Agarwal, C. Saha, M. Battiwala et al., “A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy,” Kidney International, vol. 68, no. 1, pp. 285–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Katavetin, S. Eiam-Ong, and S. Suwanwalaikorn, “Pioglitazone reduces urinary protein and urinary transforming growth factor-β excretion in patients with type 2 diabetes and overt nephropathy,” Journal of the Medical Association of Thailand, vol. 89, no. 2, pp. 170–177, 2006. View at Google Scholar · View at Scopus
  18. H. M. Jin and Y. Pan, “Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy,” Kidney and Blood Pressure Research, vol. 30, no. 4, pp. 203–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. H. Draper and M. Hadley, “A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde,” Xenobiotica, vol. 20, no. 9, pp. 901–907, 1990. View at Google Scholar · View at Scopus
  20. E. Beutler, O. Duron, and B. M. Kelly, “Improved method for the determination of blood glutathione,” The Journal of Laboratory and Clinical Medicine, vol. 61, pp. 882–888, 1963. View at Google Scholar · View at Scopus
  21. H. Aebi, S. R. Wyss, B. Scherz, and F. Skvaril, “Heterogeneity of erythrocyte catalase II. Isolation and characterization of normal and variant erythrocyte catalase and their subunits,” European Journal of Biochemistry, vol. 48, no. 1, pp. 137–145, 1974. View at Google Scholar · View at Scopus
  22. N. K. Cortas and N. W. Wakid, “Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method,” Clinical Chemistry, vol. 36, no. 8 I, pp. 1440–1443, 1990. View at Google Scholar · View at Scopus
  23. Y. Sun, L. W. Oberley, and Y. Li, “A simple method for clinical assay of superoxide dismutase,” Clinical Chemistry, vol. 34, no. 3, pp. 497–500, 1988. View at Google Scholar · View at Scopus
  24. American Diabetes Association (ADA 2009), “Standards of medical care in diabetes 2009,” Diabetes Care, vol. 32, supplement 1, pp. S13–S61, 2009. View at Publisher · View at Google Scholar
  25. E. J. Lewis, L. G. Hunsicker, R. P. Bain, R. D. Rohde, and The Collaborative Study Group, “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,” The New England Journal of Medicine, vol. 329, no. 20, pp. 1456–1462, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Moussa, “Oxidative stress in diabetes mellitus,” Romanian Journal of Biophysics, vol. 18, no. 3, pp. 225–236, 2008. View at Google Scholar
  27. T. J. Hsieh, P. Fustier, C. C. Wei et al., “Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells,” Journal of Endocrinology, vol. 183, no. 3, pp. 535–550, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, “Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells,” Diabetes, vol. 46, no. 11, pp. 1733–1742, 1997. View at Google Scholar · View at Scopus
  29. J. W. Baynes and S. R. Thorpe, “Role of oxidative stress in diabetic complications: a new perspective on an old paradigm,” Diabetes, vol. 48, no. 1, pp. 1–9, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Z. Kȩdziora-Kornatowska, M. Luciak, J. Blaszczyk, and W. Pawlak, “Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 13, no. 11, pp. 2829–2832, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. P. A. Craven, F. R. Derubertis, V. E. Kagan, M. Melhem, and R. K. Studer, “Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-β, and glomerular size in diabetes,” Journal of the American Society of Nephrology, vol. 8, no. 9, pp. 1405–1414, 1997. View at Google Scholar · View at Scopus
  32. M. Tanimoto, Q. Fan, T. Gohda, T. Shike, Y. Makita, and Y. Tomino, “Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice,” Metabolism: Clinical and Experimental, vol. 53, no. 11, pp. 1473–1479, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt, “Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity,” Hypertension, vol. 43, no. 1, pp. 48–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. X. F. Zhang and B. K. H. Tan, “Antihyperglycaemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 27, no. 5-6, pp. 358–363, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Faure, P. Corticelli, M. J. Richard et al., “Lipid peroxidation and trace element status in diabetic ketotic patients: influence of insulin therapy,” Clinical Chemistry, vol. 39, no. 5, pp. 789–793, 1993. View at Google Scholar · View at Scopus
  36. M. C. Vantyghem, M. Balduyck, F. Zerimech et al., “Oxidative markers in diabetic ketoacidosis,” Journal of Endocrinological Investigation, vol. 23, no. 11, pp. 732–736, 2000. View at Google Scholar · View at Scopus
  37. A. Gumieniczek, “Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals,” Experimental and Toxicologic Pathology, vol. 56, no. 4-5, pp. 321–326, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. A. C. Desfaits, O. Serri, and G. Renier, “Normalization of plasma lipid peroxides, adhesion, and tumor necrosis factor-α production in NIDDM patients after gliclazide treatment,” Diabetes Care, vol. 21, no. 4, pp. 487–493, 1998. View at Publisher · View at Google Scholar · View at Scopus